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Introduction
Co-administration of an agent that inhibits or induces the cytochrome P450 (CYP) Phase I drug-metabolizing enzyme systems is an important cause of adverse events and therapeutic failures for drugs with a narrow therapeutic index (Hemaiswarya and Doble, 2006; Pea and Furlanut, 2001) . However, where the CYP-modulating agent is intentionally co-administered at a titrated dose, there is potential for it to nullify the unacceptably low or variable bioavailability of a drug that undergoes extensive first pass metabolism. It is this potential that drives the development and characterization of a plethora of CYP-modulating agents as reported in the literature. To be clinically useful, however, the agent has to have a proven safety profile for human consumption, and on this basis, food-derived CYP-modulating agents, such as the spice components (SCs), curcumin (CUR), piperine (PIP) and capsaicin (CAP) (Figure 1) , can enjoy higher acceptance than novel compounds.
CUR, a polyphenolic component of turmeric (Curcuma longa), has promising therapeutic potential as an anti-cancer (Ide et al., 2010) , anti-oxidant (Hismiogullari et al., 2015) and anti-inflammatory agent (Kaur et al., 2015) . CUR is generally considered to be a safe compound, with oral doses as high as 8 g/day having been administered to humans without overt side effects (Cheng et al., 2001) . At these doses, peroral CUR has been shown to increase drug bioavailability by attenuating intestinal CYP3A expression (Zhang and Lim, 2008; Zhang et al., 2007) . CUR is also reported to be a potent inhibitor of CYP1A1, CYP1A2 and CYP2B1 activities in rat liver microsomes (Thapliyal and Maru, 2001) . In vivo, CUR administered perorally to Sprague Dawley rats at 60 mg/kg once daily over 4 days has resulted in the down-regulation of intestinal CYP3A to levels significant enough to affect the pharmacokinetic parameters of co-administered midazolam (Zhang et al., 2007) . The enhancement of docetaxel bioavailability in the rat model by CUR, co-administered at 100
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5 mg/kg for 4 consecutive days, has also been attributed in part to an inhibition of CYP3A activity (Yan et al., 2012) . PIP, the active component of black pepper (Piper nigrum Linn) and long pepper (Piper longum Linn), has also been shown, although in a smaller number of studies, to inhibit CYP enzymes. Unlike CUR, PIP is a non-competitive inhibitor of CYP3A4, and a less potent inhibitor of CYP1A2 and CYP2D6 (Volak et al., 2008) . In vivo, PIP co-administered perorally to C.B17/lcr-scid mice at 100 mg/kg (Makhov et al., 2012) , and to Swiss albino mice at 10 mg/kg (Venkatesh et al., 2011) , has been found to increase, respectively, the bioavailability of docetaxel and ibuprofen, two drugs with extensive first pass metabolic profiles.
CAP, the pungent ingredient of chilli peppers, is another SC shown to modulate CYP isozymes (Han et al., 2012; Kato et al., 2012; Takanohashi et al., 2010) . CAP at dietary concentrations may not be a CYP inhibitor, but at concentrations higher than 2.0 µM, it has been shown to inhibit CYP2D6 and CYP1A2 activities sufficiently to impact on drug metabolism (Babbar et al., 2010) . CAP may also modify the pharmacokinetic profiles of drugs that are CYP3A substrates (Hirotani et al., 2007; Zhai et al., 2013) . In rats, the administration of CAP at a dose of 3 mg/kg/day over 7 days was found to increase the plasma concentration of cyclosporine, and this was attributed to the lower expression of hepatic and intestinal CYP3A mRNA and protein levels (Zhai et al., 2013) .
Collectively, therefore, there is adequate evidence showing the SCs to be CYP inhibitors capable of interacting with drugs. The clinical potentials of PIP (Volak et al., 2008; , CUR (Volak et al., 2008; Zhang et al., 2007) and CAP (Zhai et al., 2013; Zhang et al., 2012) as CYP inhibitors have also been examined. The 3 SCs are interesting because they share similarities in chemical structures (Figure 1 ) and are complementary in taste, often coexisting in many Asian cuisines. On this basis, we hypothesized that CUR, PIP and CAP This article has not been copyedited and formatted. The final version may differ from this version. would exhibit comparable inhibitory activities against the major drug-metabolising CYP isozymes. However, there is as yet no published study that directly compares the actions of CUR, PIP and CAP on these enzymes. Data collated from reports utilising different methodologies do not allow for quantitative comparisons, and enzymes derived from human liver microsomes (HLM) and hepatocytes, particularly when the microsomes and hepatocytes are not from the same donors, would not allow for valid data comparison across laboratories or time frames. This then makes it difficult to have agreement on the relative effectiveness of the SCs that will inform clinical decisions on which SC is optimal for when a specific CYP activity is to be regulated.
The aim of the present study was to address this information gap by comparing the CYPinhibitory effectiveness of CUR, PIP and CAP using common enzyme platforms, and to ascertain whether any of the SCs was an effective inhibitor of all the tested enzymes. The enzymes studied were CYP1A2, CYP2C9, CYP2D6 and CYP3A4, which collectively account for the metabolism and disposition of about 70% of therapeutic drugs available in the market (Williams et al., 2004) . Confounding factors inherently present in biological tissues were minimized by using purified human recombinant enzymes supplied by the same manufacturer to generate the SC-mediated CYP-modulating data for comparisons. Our results showed that CAP exhibited the highest CYP-inhibitory potential, and should therefore be prioritised for further development into a pharmaceutical CYP inhibitor.
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Materials and Methods
Materials
Analytical graded dimethyl sulfoxide (DMSO) and acetonitrile (ACN) were purchased from Ajax Finechem (Taren Point, NSW, Australia). PIP (≥97%) was from SAFC Global (St Louise, MO, USA). α -naphthoflavone, ketoconazole (≥98%), sulfaphenazole (≥ 99%), CUR (≥94), CAP (≥95%) and quinidine were purchased from Sigma Chemicals (Castle Hill, NSW, Australia). CYP inhibition assays were conducted using the Vivid CYP1A2, CYP3A4, CYP2C9 and CYP2D6 Blue Screening Kits purchased from Invitrogen (Carlsbad, CA, USA).
The kits contained microsomes from baculovirus-infected cells co-expressing human CYP1A2, CYP2D6, CYP2C9, or CYP3A4, together with NADPH-cytochrome P450 reductase (P450 BACULOSOMES®) and the NADPH regeneration system containing glucose-6-phosphate and glucose-6-phosphate dehydrogenase. The kits also contained 7-benzyloxymethyloxy-3-cyanocoumarin (BOMCC) as the substrate for CYP2C9 and CYP3A4, and 7-ethylmethyloxy-3-cyanocoumarin (EOMCC) as the substrate for CYP1A2 and CYP2D6. Deionised water was used throughout.
Test and control samples
Test samples with SC concentration range of 0 to 120 μ M, the upper concentration limited by the SC solubility in the medium, were prepared by dissolving the SC in a pH 8 potassium phosphate buffer (reaction buffer supplied by manufacturer) supplemented with 0.5% DMSO. Positive control samples consisted of the manufacturer-specified inhibitor dissolved in the same medium; α -naphthoflavone (NPV, 1.7 and 10 µM) for CYP1A2, in reaction buffer) constituted the negative control sample to account for any effects of DMSO on CYP inhibition (Trubetskoy et al., 2005b) .
CYP Inhibition Assays
Assays were conducted as triplicate independent experiments for each SC according to the Vivid™ assay protocols provided by the manufacturer (https://tools.thermofisher.com/ content/sfs/brochures/VividScreeningKitManual24Apr20121.pdf). All enzyme reactions were conducted under conditions shown to be linear with respect to incubation time, amounts of enzyme and substrate (Trubetskoy et al., 2005b) . The inhibition assays were performed in 96-well plates, the final enzyme and substrate concentrations are given in Table 1 . The integrity of the recombinant enzymes was confirmed using the respective substrates with and without co-incubation with the specified positive control. A negative control sample was included in to 2500 nM. CYP activity was significantly reduced, but not negated, by co-incubation of the specified substrate and inhibitor at the concentrations recommended by the manufacturer (Figure 2 ). The extent of CYP inhibition was dependent on the inhibitor concentration, with greater suppression of the enzyme activities noted at higher inhibitor concentrations. The collective data showed that the integrity of all 4 recombinant enzyme systems was intact, and that they could be used to compare the CYP-modulating activity of the SCs.
CUR-mediated CYP inhibition
CUR was an inhibitor of all 4 recombinant enzymes, its effectiveness was dependent on its concentration and the type of CYP isozyme employed (Figure 3 ). Of the 4 CYPs, CUR was most effective at inhibiting CYP3A4, almost obliterating the enzyme function at concentrations ≥ 60 µM. It was less effective against CYP1A2, where residual enzyme levels ≥ 40% were observed even at 120 µM of CUR (Figure 3 ). Compared to the established CYP inhibitors, CUR produced comparable inhibitions at a lower concentration than SPZ (15 µM vs. 20 µM) for CYP2C9, and at higher concentrations than KCZ (30 µM vs. 5 µM) and QDN (120 µM vs. 0.6 µM) for CYP3A4 and CYP2D6, respectively. It was possible, by applying higher concentrations of CUR, to inhibit CYP2C9 and CYP3A4 to levels lower than those induced by the manufacturer-recommended inhibitors (Figure 3 ).
PIP-mediated CYP inhibition
PIP also exhibited inhibitory activity against all 4 recombinant enzymes in a manner that was influenced by its concentration and the CYP isoenzyme employed (Figure 4 ). Like CUR, PIP was most potent against CYP3A4; however, while it was able to halve the enzyme activity at a very low concentration of 2 µM, PIP produced comparable CYP3A4 inhibition to KCZ at a higher concentration (30 µM vs. 5 µM), and the CYP3A4 function could not be lowered further even when PIP was increased to 120 µM. PIP was also able to produce comparable enzyme inhibitions as the manufacturer-recommended inhibitors. However, this was achieved at higher concentrations than SPZ (30 µM vs. 20 µM) and NPV (30 µM vs. 1.7 µM) for CYP2C9 and CYP1A2, respectively, and the PIP-mediated inhibitory action on these two CYPs showed levelling effects at higher concentrations. PIP was least effective against CYP2D6, where the residual enzyme activity at 120 µM of PIP was significantly higher than that seen with 0.6 µM of QDN.
CAP-mediated CYP inhibition
CAP was an effective inhibitor of all 4 recombinant isozymes, lowering the enzyme activities to match those seen with the established inhibitors ( Figure 5 ), although CAP achieved this at relatively higher concentrations. The exception was CYP2C9, where the inhibitory action of CAP at 10 µM was comparable to that of SPZ at 20 µM, and higher levels of enzyme inhibition were noted on increasing CAP to ≥ 60 µM. With CYP3A4, CAP exhibited an inhibitory profile that has characteristics seen with PIP (strong inhibition at low concentrations) and CUR (concentration-dependent inhibition even at higher concentrations).
This article has not been copyedited and formatted. The final version may differ from this version. (Table 2) . Based on the relative IC 50 values, the ranking order of inhibitory potential against CYP1A2 was CAP > PIP > CUR, while the 3 SCs were equally weak at inhibiting CYP2D6. CAP and PIP were comparable in their inhibitory potential against CYP3A4, and this was > 5 fold higher than that seen with CUR. In contrast, CUR was comparable in inhibitory potential to CAP against the CYP2C9, the inhibitory potential being > 6-fold higher than that observed with PIP.
IC 50 values for the manufacturer-recommended inhibitors have been published for a variety of enzyme platforms employed ( 
Discussion
The aim of this study was to evaluate the comparative capability of CUR, PIP and CAP to inhibit 4 major human CYP isozymes responsible for drug bioavailability and disposition.
Studies investigating SC-mediated inhibition of CYP functional activities are not new.
However, as shown in Table 3 , the published IC 50 data for a SC-CYP combination typically span a broad range of values, depending on the SC grade, enzyme source, substrate, inhibitor and assay method employed. This then makes it difficult to use the published IC 50 values to accurately assess the comparative CYP-inhibitory potency of the SC.
In this study, we employed a common high throughput CYP enzyme assay kit to evaluate the 3 SCs against a specific CYP activity. The recombinant enzyme system may be more costly and less representative of physiological conditions, but it is a more consistent platform that avoids the wide variability in enzyme expression and activity normally encountered in HLM (Snawder and Lipscomb, 2000) and hepatocytes (Rodriguez-Antona et al., 2002; Westerink and Schoonen, 2007) . Also, the enzyme systems are highly specific and relatively stable, with no significant loss in activity noted after 7 h at room temperature (Trubetskoy et al., 2005b) . Fluorescent high throughput screening methods employ fluorescent P450
substrates that are efficiently metabolized by specific P450 isozymes to yield a product with altered fluorescent properties, usually increased fluorescent intensity (Trubetskoy et al., 2005b) . The assay requires only low reactant volume to produce high signal-to-background ratio, which allows multiple SCs to be evaluated using the same batch of recombinant CYP -Opong et al., 2007; Bamba et al., 2011; Volak et al., 2008) , and PIP exhibiting stronger inhibition of CYP3A4 and CYP1A2 (Volak et al., 2008) . CUR has been reported to demonstrate moderate inhibitory action on CYP2C9, 2C19 and 2B6 activities in the HLM (Volak et al., 2008) , and CYP3A4, 2C9, 2D6 and 1A2-mediated metabolism of fluorogenic probe substrates in recombinant enzyme systems (Appiah-Opong et al., 2007) .
The rank order for CAP-mediated CYP inhibition was less consistent with the published literature. In the present study, CAP was more active against the CYP3A4 and CYP1A2, while Babbar et al. (2010) reported stronger activity of CAP against CYP1A2 and CYP2C9, and Zhang et al. (2012) showed CAP to be more active against CYP2C9 than against CYP1A2, CYP3A4 and CYP2D6. Nevertheless, if we were to examine the threshold CAP concentrations that attained equivalency of activity to the manufacturer-recommended inhibitors (Figure 4 ), CAP would be classified as having stronger activity against CYP1A2
and CYP2C9, a position more in line with the published data.
The clinical significance of our data is dependent on the dose and bioavailability of the SC, the relative binding affinity of SC to specific CYP in biological milieu, and the mechanism of inhibition involved. The concentrations of SC employed in the present study were adequate for pharmacological interventions. CUR, for example, showed chemoprevention and other biochemical modulations at 5 to 50 µM (Yallapu et al., 2014; Zhang et al., 2012) , while CAP and PIP had effective pharmacological concentrations at 1 to 250 µM (Han et al., 2006; Lin et al., 2013; Zhang et al., 2012) , and 10 to 100 µM (Han et al., 2008; Volak et al., 2008; Wang et al., 2013) , respectively. However, the extremely low peroral bioavailability of CUR, which yielded low plasma concentrations in the nM range This article has not been copyedited and formatted. The final version may differ from this version. (Sharma et al., 2001 ), could present a challenge for this SC to be applied for systemic CYP inhibition. Maximum CAP plasma concentrations following consumption of 5 g of chilli peppers or administration of a cutaneous patch (640 µg/cm 2 of CAP) were also relatively low, at 8.1 nM (Chaiyasit et al., 2009 ) and 58 nM (Babbar et al., 2009) , respectively. To our best knowledge, there has been no report on the bioavailability of PIP but, given its structural similarity to CUR and CAP (Suresh and Srinivasan, 2006; Suresh and Srinivasan, 2010) , PIP is likely to also present in the nM range after oral administration. Although significant systemic CYP functional inhibition appears unattainable, given the IC 50 values are in the µM range, published reports involving the ingestion of relatively high doses of purified SC have indicated otherwise. CUR administered orally at 60 mg/kg/day for 4 days had been shown to affect intestinal CYP protein expression and increase midazolam bioavailability in the rat model (Zhang et al., 2007) . PIP at a single oral dose of 50 mg/kg could inhibit hepatic CYP3A4 activity in the mouse model, while a higher dose of 100 mg/kg significantly increased and prolonged the plasma levels of co-administered docetaxel, an anticancer drug (Makhov et al., 2012) . Oral administration of CAP at 30 mg/kg to the Wistar rats has also significantly increased the bioavailability and maximum plasma concentration of coadministered phenytoin, an anti-epileptic drug of narrow therapeutic index and a substrate of CYP2C9 (Hirotani et al., 2007) .
The small intestine is also a major site of CYP metabolic activities, at levels comparable to those in the liver (Ortiz de Montellano, 1995; Wacher et al., 1998) . Considering the volume of GI fluid to be approximately 8 L (Lawson, 2003) , a typical Indian diet comprising 0.87 g/day of turmeric (3 -5% CUR) (Pradeep et al., 1993) would result in a CUR concentration as high as 10 µM in the gastrointestinal (GIT). Likewise, populations that use black pepper regularly in their diets may consume about 0.34 g/day of black pepper (5 -9% PIP) (Bhardwaj et al., 2002) , which translates to approximately 7.5 to 13.8 µM of PIP in the This article has not been copyedited and formatted. The final version may differ from this version. GIT. CAP content in red hot peppers ranges from 0.1 to 1% (Govindarajan and Sathyanarayana, 1991) , and a typical Indian or Thai diet involving a daily CAP intake of about 9 mg (Rumsfield and West, 1991) would introduce 3 µM of CAP into the GI fluid.
High daily intake of CAP is not unusual. In some South-East Asian countries, the average daily per capita consumption of CAP is as high as 50 mg (Buck and Burks, 1983) while residents in some parts of China are reported to consume up to 150 mg of CAP daily .
It is therefore not inconceivable that perorally administered SC could present at sufficiently high levels to produce significant interactions with intestinal CYPs -CYP3A4
and CYP2C9 could be particularly susceptible, with CYP1A2 also potentially sensitive to modulation by CAP and PIP. On this basis, caution may be exercised concerning the coconsumption of SCs and drugs whose metabolism and bioavailability are governed by CYP3A4, CYP1A2 and/or CYP2C9 activities. Undesirable SC-drug interactions could be compounded when the 3 SCs are consumed together, which is common in many Asian cuisines. In conclusion, data from the present study demonstrate that PIP and CAP are relatively strong inhibitors of at least 3 major human CYP enzymes, namely CYP2C9, CYP1A2 and CYP3A4, while CUR is a strong inhibitor of CYP2C9 and CYP3A4. Of the 3
SCs, CAP has the strongest potential as a CYP inhibitor.
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